Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPAS1 | Q99814 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | APLNR | P35414 | 3/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | ALPL | P05186 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL779828 | 0.82 | EPAS1 (0.50) | EPAS1TSHRPTGS1PTGS2 | |
| SCHEMBL31305332 | 0.82 | EPAS1 (0.50) | EPAS1TSHRPTGS1PTGS2 | |
| SCHEMBL6139736 | 0.81 | RAB9A (0.40) | EPAS1ALDH1A1LMNAPOLB | |
| SCHEMBL6139651 | 0.81 | TSHR (0.41) | EPAS1ALDH1A1LMNAPOLBTSHR | |
| SCHEMBL18482393 | 0.80 | ALPL (0.44) | ALPL | |
| SCHEMBL8359389 | 0.79 | EPAS1 (0.46) | EPAS1SLC6A4PTGS1PTGS2 | |
| SCHEMBL28741529 | 0.79 | EPAS1 (0.41) | EPAS1ALDH1A1 | |
| SCHEMBL4769962 | 0.79 | PTGDR2 (0.42) | EPAS1TSHRALPL | |
| SCHEMBL6511762 | 0.79 | DRD2 (0.39) | ALDH1A1LMNATSHRSLC6A4 | |
| SCHEMBL25353653 | 0.78 | ALPL (0.36) | EPAS1TSHRAPLNRALPL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7754103-B2 | Liquid-crystalline medium | MERCK PATENT GMBH (DE) | 2010-07-13 | — | — | US | disclosed |
| US-7732021-B2 | Liquid crystalline medium | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-06-08 | — | — | US | disclosed |
| US-7635505-B2 | Liquid Crystalline Medium | MERCK PATENT GMBH (DE) | 2009-12-22 | — | — | US | disclosed |
| US-20090194738-A1 | Liquid-crystalline medium | MANABE ATSUTAKA | 2009-08-06 | — | — | US | disclosed |
| US-20080277623-A1 | Liquid Crystalline Medium | MERCK PATENT GMBH (DE) | 2008-11-13 | — | — | US | disclosed |
| US-20080128653-A1 | Liquid Crystalline Medium | MERCK PATENT GMBH (DE) | 2008-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080277623-A1 | Liquid Crystalline Medium | CHRM1, NEFM, CCNT1 | EPAS1 4116/4885ALDH1A1 2497/4885LMNA 80/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.